A Katten team represented Deerfield Management Company, L.P. in the successful acquisition of publicly-held Singular Genomics Systems, Inc.
The transaction, which closed on February 21, 2025, involved a newly formed holding company owned by Deerfield acquiring outstanding shares of Singular Genomics common stock for $20 per share in cash. In lieu of receiving cash consideration, several of Singular Genomics' stockholders, including Deerfield, converted outstanding shares of Singular Genomics' into equity interests in the post-closing holding company. With the completion of this acquisition, Singular Genomics has transitioned to operating as a private company, a move intended to provide Singular Genomics with greater flexibility in advancing its strategic objectives.
The Katten team was led by Capital Markets Partner and Co-Chair Mark Wood and Mergers and Acquisitions Partner Josh Feiger and included Capital Markets Partner Jonathan Weiner and Associates Michelle Mount and Kyle Warbinton; Mergers and Acquisitions Associates Kylie Sholty and Adam Hansen; Employee Benefits and Executive Compensation Partner Mitchel Pahl and Associate Neal Patel; Corporate Labor and Employment Partner Michelle Gyves; Tax Partner Jill Darrow; and Intellectual Property Partner Sean Wooden and Associate Yaesul Park.
"Singular Genomics Announces Closing of Acquisition by Deerfield Management," Global Newswire, February 21, 2025.